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Abstract
Background: The antimicrobial resistance of clinical, environmental and control strains of the WHO “Priority 1:
Critical group” organisms, Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae and Pseudomonas
aeruginosa to various classes of antibiotics, colistin and surfactin (biosurfactant) was determined.
Methods: Acinetobacter baumannii was isolated from environmental samples and antibiotic resistance profiling was
performed to classify the test organisms [A. baumannii (n = 6), P. aeruginosa (n = 5), E. coli (n = 7) and K. pneumoniae
(n = 7)] as multidrug resistant (MDR) or extreme drug resistant (XDR). All the bacterial isolates (n = 25) were screened
for colistin resistance and the mobilised colistin resistance (mcr) genes. Biosurfactants produced by Bacillus
amyloliquefaciens ST34 were solvent extracted and characterised using ultra-performance liquid chromatography
(UPLC) coupled to electrospray ionisation mass spectrometry (ESI–MS). The susceptibility of strains, exhibiting antibiotic
and colistin resistance, to the crude surfactin extract (cell-free supernatant) was then determined.
Results: Antibiotic resistance profiling classified four A. baumannii (67%), one K. pneumoniae (15%) and one P.
aeruginosa (20%) isolate as XDR, with one E. coli (15%) and three K. pneumoniae (43%) strains classified as MDR. Many of
the isolates [A. baumannii (25%), E. coli (80%), K. pneumoniae (100%) and P. aeruginosa (100%)] exhibited colistin
resistance [minimum inhibitory concentrations (MICs)≥ 4mg/L]; however, only one E. coli strain isolated from a clinical
environment harboured the mcr-1 gene. UPLC-MS analysis then indicated that the B. amyloliquefaciens ST34 produced
C13–16 surfactin analogues, which were identified as Srf1 to Srf5. The crude surfactin extract (10.00mg/mL) retained
antimicrobial activity (100%) against the MDR, XDR and colistin resistant A. baumannii, P. aeruginosa, E. coli and K.
pneumoniae strains.
Conclusion: Clinical, environmental and control strains of A. baumannii, P. aeruginosa, E. coli and K. pneumoniae
exhibiting MDR and XDR profiles and colistin resistance, were susceptible to surfactin analogues, confirming that this
lipopeptide shows promise for application in clinical settings.
Keywords: Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Colistin resistance,
Surfactin
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Background
Bacterial antibiotic resistance is a global public health
crisis and in 2017, the World Health Organisation
(WHO) created a list of 12 genera and/or families, which
were prioritised for the development of alternative anti-
microbials into the categories critical, high and medium.
Carbapenem-resistant Acinetobacter baumannii (A.
baumannii) was classified as one of the main “Priority
1: Critical group” organisms [1] as it is the primary
opportunistic pathogen implicated in nosocomial infec-
tions such as; bacteraemia, pneumonia, endocarditis, men-
ingitis and catheter associated urinary tract infections
(UTIs) [2–4]. It is also the primary species detected and
isolated from hospital environments, including intensive
care units (ICUs), with many other Acinetobacter species
frequently isolated from soil, water, vegetables and animal
sources [5]. Pseudomonas aeruginosa (P. aeruginosa), the
second carbapenem-resistant bacterium listed in the “Pri-
ority 1: Critical group”, can be found in a diverse range of
habitats and is classified as an opportunistic pathogen in
animal or plant hosts [6]. Several P. aeruginosa strains
have also been isolated from hospital environments and
have been implicated in nosocomial infections. This op-
portunistic pathogen primarily infects the immunocom-
promised and elderly and has been identified as the
causative agent in burn wound infections, as the biofilm
coloniser of medical devices and causes lung infection in
cystic fibrosis patients [7, 8]. A study by Tam et al. [9] also
revealed that patients infected with MDR P. aeruginosa
were hospitalised for a significantly longer time period
and were at an increased risk for 30-day mortality.
Escherichia coli and K. pneumoniae are members of
the family Enterobacteriaceae, which is classified as
carbapenem-resistant, 3rd generation cephalosporin-
resistant bacteria [1]. Escherichia coli is predominantly
found in soil and aquatic environments; however, it is
also present in the lower gastrointestinal tract of warm-
blooded animals and in reptiles [10, 11]. Enteric or intes-
tinal E. coli strains can be classified into pathotypes
based on phenotypic traits and specific virulence factors
[12], with UTI’s, gastroenteritis, meningitis, peritonitis
and septicaemia in hospital settings commonly caused
by various strains of E. coli [13, 14]. Klebsiella pneumo-
niae is an opportunistic pathogen found in several envir-
onmental niches such as soil, plants and water. It is a
common skin commensal and inhabits the gastrointes-
tinal tract and nasopharynx of animals and humans [15].
Due to its presence on or in humans and animals it is
responsible for several systemic infections such as UTIs,
bacteraemia and pneumonia [16].
The global emergence of clinical infections due to
multidrug resistant (MDR) and extreme drug resistant
(XDR) strains of the “Priority 1: Critical group” has sub-
sequently led to a resurgence of the last-resort antibiotic
colistin (polymyxin E) [17–19]. However, while colistin
resistance was previously considered to be a rare
chromosomal mutation, in 2015 a novel method of plas-
mid mediated colistin resistance was documented, when
a mobilised colistin resistance gene (mcr-1), identified
on an IncI2 plasmid, pHNSHP45, was isolated by Liu
et al. [20] from pigs in China. A study performed by
Newton-Foot et al. [21] detected colistin resistance
encoded by the mcr-1 gene in isolates of E. coli and K.
pneumoniae, amongst others, obtained from eight differ-
ent hospitals in the Western Cape region of South
Africa. Following the detection of the mcr-1 gene, sev-
eral other mcr genes have been detected: mcr-2 harbour-
ing E. coli isolated in Belgium [22]; mcr-3 harbouring E.
coli isolated from swine in China [23]; mcr-4 harbouring
Enterobacteriaceae species (E. coli and Salmonella enter-
ica serovar Typhimurium) isolated form pigs in Belgium,
Italy and Spain [24]; and mcr-5 carrying Salmonella
Paratyphi B dTa + isolated from animals in Germany
[25]. While, the mechanism of colistin resistance in A.
baumannii and P. aeruginosa has not been fully eluci-
dated, the rate at which bacterial pathogens are exhibit-
ing resistance to this last-resort treatment is rapidly
increasing, which implies that novel strategies or alterna-
tive antimicrobials are urgently required to combat
MDR and XDR bacteria.
Biosurfactants are secondary metabolites, synthesised
non-ribosomally by bacteria, yeast and fungi during the
exponential and/or stationary growth phases [26, 27].
They can be classified into six major groups, however
glycolipids (e.g. rhamnolipids, sophrose lipids, trehalose
lipids) and lipopeptides (e.g. surfactin, viscosin, serrawet-
tin) are of extreme interest to the medical field as vari-
ous classes exhibit broad-spectrum antimicrobial activity
[28]. The widely studied lipopeptide, surfactin, has sub-
sequently been utilised as an anti-inflammatory, anti-
adhesive, antiviral and antibacterial agent and has also
been employed in bioremediation strategies [27, 29].
This lipopeptide is generally synthesised by Bacillus spe-
cies and consists of an amphipathic cyclic heptapeptide
with a chiral sequence (L-Glu, L-Leu, D-Leu, L-Val, L-
Asp, D-Leu, L-Leu) linked to a β-hydroxy fatty acid
group comprised of 13 to 16 carbon atoms [30, 31].
Ndlovu et al. [27] investigated the antimicrobial activity
of a crude surfactin extract obtained from a Bacillus
amyloliquefaciens (B. amyloliquefaciens) ST34 strain
against various pathogenic bacteria, fungi and yeast. The
extract produced pronounced antimicrobial activity
against the antibiotic resistant Staphylococcus aureus
(Methicillin Resistant S. aureus – MRSA), E. coli and the
opportunistic pathogenic yeast strain Candida albicans.
The primary aim of the current study was to explore
the antimicrobial resistance profiles of clinical, environ-
mental and control strains of the WHO “Priority 1:
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Critical group” organisms, A. baumannii, P. aeruginosa,
E. coli and K. pneumoniae. Various experimental tasks
were performed to achieve this aim including the isola-
tion of A. baumannii from environmental samples. The
antibiotic resistance profiles of the A. baumannii, P.
aeruginosa, E. coli and K. pneumoniae strains were
subsequently analysed against an array of antibiotics,
whereafter the colistin resistance profile of the isolates
exhibiting multidrug resistance was determined. Finally,
the susceptibility of the clinical, environmental and con-
trol strains, exhibiting multidrug and colistin resistance,
to the crude extract of surfactin was determined.
Results
Isolation of A. baumannii and sequence-based
identification of test strains
Based on morphological characterisation, three isolates
from the Stellenbosch WWTP, seven isolates from the
Plankenburg River and six isolates from the stream in
Enkanini informal settlement were presumptively identi-
fied as A. baumannii. In order to confirm the identity of
these isolates, as well as the reference and clinical strains
of A. baumannii and the reference, clinical and environ-
mental strains of E. coli, K. pneumoniae and P. aerugi-
nosa (obtained from the various culture collections),
genus or species-specific conventional PCR and DNA se-
quencing was performed. It should be noted that the
strains used in the current study were assigned code
name identifiers as outlined in Additional file 1: Table
S1. Henceforth the isolates will be referred to by their
code identifiers. Furthermore, the GenBank accession
numbers are listed in Additional file 1: Table S1.
Conventional PCR and sequencing of the A.b_hyp
gene (545 bp) identified one of the 16 presumptive iso-
lates as A. baumanii (CP030106.1). The A. baumannii
isolate (AB 6) was obtained from the Enkanini informal
settlement stream sample using growth media specific
for Campylobacter species [32]. Sequencing analysis then
confirmed the identity of the A. baumannii ATCC refer-
ence strain (AB 1) and the clinical isolates (AB 2 to AB
5; Additional file 1: Table S1).
Sequencing of the amplified phoA gene (903 bp) con-
firmed the identity of all the E. coli reference (EC 1), clin-
ical (EC 2 and EC 3) and environmental (EC 4 – EC 7)
isolates used in the current study (Additional file 1: Table
S1). Similarly, the identity of all the K. pneumoniae isolates
[reference (KP 1), clinical (KP 1 – KP 3) and environmen-
tal (KP 5 – KP 7)] was confirmed by conventional PCR
and sequencing of the Klebsiella gyrA gene (383 bp), while
the identity of all the P. aeruginosa isolates [reference (PA
1), clinical (PA 2 and PA 3) and environmental (PA 4 and
PA 5)] used in the current study was confirmed using
conventional PCR and sequencing targeting the16S rRNA
region (618 bp) within the Pseudomonas genome.
As a quality control step, conventional PCR and se-
quencing thus confirmed the identity of the reference,
clinical and environmental isolates as A. baumannii
(n = 6), E. coli (n = 7), K. pneumoniae (n = 7) and P. aer-
uginosa (n = 5).
Kirby-Bauer antibiotic assays
The respective bacterial isolates (n = 25) were subjected
to various antibiotics (Additional file 1: Table S2)
[33, 34], with the results of the Kirby-Bauer Antibiotic
Assays summarised in Fig. 1 and Additional file 1: Figure
S1. Zones of inhibition were measured and compared to
the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) [33] and Clinical and Laboratory
Standard Institute (CLSI) [34] breakpoints.
The antimicrobial susceptibility analysis indicated that
the A. baumannii isolates AB 1 (reference strain) and
AB 6 (environmental strain) exhibited low resistance to-
wards the antibiotics analysed (Fig. 1). In contrast, based
on the EUCAST [33] breakpoints, the clinical isolates
AB 2 to AB 5 were resistant to 100% of the tested antibi-
otics (Fig. 1) and based on the CLSI [34] breakpoints,
AB 2 to AB 4 (exception of tetracycline where an inter-
mediate result was recorded) were resistant to all the an-
tibiotics analysed; while AB 5 displayed resistance to
73% (8/11) of the analysed antibiotics. The four clinical
A. baumannii isolates (AB 2 – AB 5) thus displayed re-
sistance to β-lactam antibiotics, fluoroquinolones and
aminoglycosides as well as to carbapenems and were
classified as XDR.
According to both the EUCAST [33] and CLSI [34]
breakpoints, the reference EC 1 isolate was susceptible
to 100% of the tested antibiotics (Fig. 1). Similarly, iso-
lates EC 3 to EC 5 exhibited intermediate susceptibility
and susceptibility to most of the antibiotics analysed
(Fig. 1) [33, 34]. In contrast, the clinical EC 2 isolate was
resistant to 67% (8/12), intermediately susceptible to 8%
(1/12) and susceptible to 25% (3/12) of the tested antibi-
otics according to the EUCAST [33] breakpoints. In ac-
cordance with the CLSI [34] breakpoints, EC 2 also
displayed resistance to 62% (8/13) of the antibiotics ana-
lysed, while intermediate susceptibility and susceptibility
was recorded against 23% (3/13) and 15% (2/13), re-
spectively, of the tested antibiotics. The clinical E. coli
isolate EC 2 thus exhibited resistance to β-lactams,
fluoroquinolones and aminoglycosides and was charac-
terised as MDR.
While the environmental KP 5 to KP 7 strains dis-
played susceptibility and intermediate susceptibility to
most of the antibiotics analysed, the reference KP 1 iso-
late displayed resistance to 58% (7/12), intermediate sus-
ceptibility to 17% (2/12) and susceptibility to 25% (3/12)
of the tested antibiotics according to the EUCAST [33]
breakpoints (Fig. 1). However, based on the CLSI [34]
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breakpoints, KP 1 displayed resistance to 38% (5/13),
intermediate susceptibility to 23% (3/13) and susceptibil-
ity to 38% (5/13) of the tested antibiotics. Based on the
EUCAST [33] and CLSI [34] breakpoints, the clinical KP
2 and KP 3 strains displayed similar profiles and were re-
sistant to the majority of the antibiotics tested (Fig. 1).
Furthermore, the clinical KP 4 exhibited the same anti-
biotic profile as KP 3, however, it was also resistant to
piperacillin-tazobactam (TZP) [33]. Based on the CLSI
[34] breakpoints, isolates KP 3 and KP 4 again displayed
similar antibiotic profiles, with the exception that KP 3
was susceptible to amikacin while intermediate suscepti-
bility was recorded for KP 4, and KP3 was susceptible to
tetracycline (TE), while KP 4 was resistant. The refer-
ence KP 1 and clinical KP 2 and KP 3 isolates were sub-
sequently classified as MDR as they exhibited resistance
to the three antibiotic classes β-lactams, fluoroquino-
lones and aminoglycosides, while KP 4 was classified as
XDR and exhibited resistance to the three antibiotic
classes including carbapenems [imipenem (IMP)].
According to the EUCAST [33] breakpoints all P. aer-
uginosa isolates (PA 1 – PA 5) exhibited resistance to
the antibiotics ceftazidime (CAZ), ciprofloxacin (CIP),
levofloxacin (LEV) and meropenem (MEM). However,
based on the CLSI [34] breakpoints the P. aeruginosa
isolates were only classified as resistant to ceftazidime
(CAZ) and meropenem (MEM). Both the EUCAST [33]
and CLSI [34] breakpoints classified the clinical isolate
PA 3 as 100% resistant to all tested antibiotics and it was
subsequently classified as XDR.
Colistin resistance of isolates exhibiting antibiotic
resistance
Based on the results obtained for the antibiotic suscepti-
bility assays, the MIC of 16 isolates (reference and repre-
sentative MDR and XDR strains) (Table 1), against the
last resort antibiotic colistin, was determined. Based on
the EUCAST [33] and CLSI [34] breakpoints, a colistin
MIC of ≥4 mg/L was recorded for 11 of the 16 isolates
analysed, while PA 2 displayed a colistin MIC of 8 mg/L
(Table 1). The reference isolate AB 1, the clinical isolate
AB 2, the environmental isolate AB 6 and the clinical
isolate EC 2 exhibited colistin MICs of 2 mg/L based on
the EUCAST [33] and CLSI [34] breakpoints. As varying
degrees of colistin resistance were recorded for the test
isolates, colistin resistance mediated by the mcr-genes
was determined [19]. Subsequently, all the organisms
were screened for the plasmid-mediated mobilised colis-
tin resistance genes (mcr-1 to mcr-4) using conventional
PCR. Results indicated that only the clinical EC 3 isolate
(colistin MIC ≥4 mg/L) contained the mcr-1 gene, while
all the other isolates were negative for the mcr-1, mcr-2,
mcr-3 and mcr-4 genes.
Table 1 Colistin MICs and antimicrobial activity of
biosurfactant extract ST34 (10.00 mg/mL) against a
panel (n = 16) of MDR and XDR bacterial isolates.
Fig. 1 Antibiotic susceptibility profiles of all test organisms as determined by disc diffusion assays and classified according to the EUCAST [33]
and CLSI [34] guidelines. Resistant (R; Red); Intermediate (I; Orange); Susceptible (S; Green); Thin diagonal stripes = Data not available (N/A),
antibiotics not tested. Amikacin (AK), Ampicillin (AMP), Aztreonam (ATM), Cefepime (FEP), Cefotaxime (CTX), Ceftazidime (CAZ), Ciprofloxacin (CIP),
Gentamicin (CN), Imipenem (IMP), Levofloxacin (LEV), Meropenem (MEM), Piperacillin-tazobactam (TZP), Tetracycline (TE)
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Characterisation of Surfactin produced by the B.
amyloliquefaciens ST34 strain using UPLC-ESI-MS
Ndlovu et al. [27] isolated the B. amyloliquefaciens ST34
strain from a WWTP in Stellenbosch. The spectra of the
ST34 extract was thus compared to the surfactin stand-
ard (Sigma-Aldrich) and literature [27, 35]. The ion
spectra in positive (ESI-MS) mode showed that the bio-
surfactant produced by ST34 displayed a profile similar
to that of the surfactin standard (Additional file 1: Figure
S2). The ESI-MS spectrum of the ST34 extract and the
surfactin standard revealed five groups of analogue mol-
ecules (Additional file 1: Figure S2).
Table 2 Summary of the detected surfactin lipopep-
tides extracted from MSM cultured B. amyloliquefaciens
ST34, as detected using UPLC-ESI-MS.
The positive mode spectra of the ST34 extract (Table 2)
and the surfactin standard (results not shown) displayed
five main groups of molecular ion m/z 994.65, 1008.66,
1022.68, 1036.69, and 1050.71 corresponding to the singly
protonated charged species [M+H]+. Their correspond-
ing sodium adducts [M+Na]+ were detected at m/z
1016.62, 1030.64, 1044.66, 1058.68 and 1072.69 (Table 2;
Additional file 1: Figure S2). The surfactin species with
longer fatty acyl chains were expected to elute later with a
higher retention time (Rt) [27]. This was observed in the
UPLC-MS profile of the ST34 extracts with the surfactin
groups eluting as follows; surfactin group 1 (Srf1) (Rt 10.6;
11.2min), Srf2 (Rt 11.0; 11.2; 11.9min), Srf3 (Rt 11.6; 11.7;
12.3min), Srf4 (Rt 12.1; 12.2min) and Srf5 (Rt 12.6; 12.7
min) (Additional file 1: Figure S2). The surfactin groups in
the ST34 extract corresponding to the C13, C14, C15 and
C16 (Srf1–5) analogues in the surfactin standard were also
observed to have more than one retention time even
though they displayed identical m/z and Mr values. The
Srf3 and Srf4 analogues were present at the highest per-
centage of 42.1 and 34.9%, respectively, while the Srf1,
Srf2 and Srf5 analogues contributed 5.6, 12.8 and 4.6% to
the ST34 crude extract, respectively.
Antimicrobial activity of Surfactin: agar disc susceptibility
assay
The 16 isolates analysed for colistin resistance were also
used as test strains for the assessment of the antimicro-
bial activity of the crude extract obtained from B. amylo-
liquefaciens ST34. Overall, antibacterial activity was
observed against all test organisms utilised in this study
(Table 1), with varying diameters for the zones of inhib-
ition recorded.
For the A. baumannii isolates, the ST34 extract dis-
played the lowest activity against the environmental AB
6 isolate with a zone of inhibition of 11.7 ± 1.2 mm re-
corded, while the highest zone of inhibition was ob-
tained against the XDR and colistin resistant clinical
isolate AB 4 at 17.3 ± 0.6 mm (Table 1). An average zone
of inhibition of 14.3 ± 2.3 mm was observed for the A.
baumannii isolates. For E. coli, the highest zone of
Table 1 Colistin MICs and antimicrobial activity of biosurfactant extract ST34 (10.00 mg/mL) against a panel (n = 16) of MDR and
XDR bacterial isolates
Organism Strain
Code
Source Colistin MIC (mg/L) Antimicrobial inhibition zone
diameter (mm) ± SD
Surfactin Extract
A. baumannii AB 1 ATCC 2 (S) 13.3 ± 1.2
AB 2 Clinical 2 (S) 14.7 ± 0.6
AB 4 Clinical > 4a (R) 17.3 ± 0.6
AB 6 Environmental 2 (S) 11.7 ± 1.2
E. coli EC 1 ATCC 4 (R) 12.7 ± 0.6
EC 2 Clinical 2 (S) 15.7 ± 0.6
EC 3 Clinical > 4a (R) 15.7 ± 1.6
EC 4 Environmental 4 (R) 14 ± 0
EC 5 Environmental 4 (R) 17.7 ± 0.6
K. pneumoniae KP 1 ATCC 4 (R) 14.3 ± 0.6
KP 4 Clinical 4 (R) 13.3 ± 0.6
KP 5 Environmental > 4a (R) 13 ± 1
P. aeruginosa PA 1 ATCC 4 (R) 13 ± 0
PA 2 Clinical 8 (R) 13 ± 0
PA 3 Clinical 4 (R) 13.3 ± 0.6
PA 4 Environmental 4 (R) 12.7 ± 0.6
aCorresponds to a colistin concentration exceeding 4 mg/L; S susceptible; R resistant
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inhibition (17.7 ± 0.6 mm) was obtained for the environ-
mental colistin resistant EC 5 isolate, while the lowest
zone of inhibition was observed for the reference EC 1
isolate at 12.7 ± 0.6 mm (Table 1). Overall the E. coli iso-
lates displayed an average zone of inhibition of 15.1 ±
1.8 mm. In contrast, the reference KP 1 isolate displayed
the highest zone of inhibition at 14.3 ± 0.6 mm, while the
environmental colistin resistant KP 5 isolate displayed
the lowest zone of inhibition at 13 ± 1mm (Table 1).
The K. pneumoniae isolates displayed an average zone of
inhibition of 13.6 ± 0.9 mm. All P. aeruginosa isolates
displayed a similar sensitivity profile against the ST34
extract, with the clinical PA 3 isolate displaying the lar-
gest zone of inhibition at 13.3 ± 0.6 and the environmen-
tal PA 4 isolate displaying the smallest zone of inhibition
at 12.7 ± 0.6 mm (Table 1). An average zone of inhibition
of 13 ± 0.4 mm was observed for the P. aeruginosa iso-
lates. In comparison to the ST34 extract, the commercial
surfactin displayed comparable or lower activity against
the reference E. coli EC 1, K. pneumoniae KP 1 and P.
aeruginosa PA 1 strains, with no activity recorded
against the A. baumannii AB 1 strain. No antimicrobial
effect was observed for the negative control.
Discussion
The efficacy of antibiotics is threatened by the rapid
emergence of clinical and environmental bacterial strains
exhibiting MDR and XDR profiles. The primary aim of
the current study was thus to classify the antimicrobial
resistance profiles of clinical, environmental and control
strains of the WHO “Priority 1: Critical group” organ-
isms, A. baumannii, E. coli, K. pneumoniae and P. aeru-
ginosa. Subsequently, the susceptibility of the strains to
various antibiotics, the last-resort antimicrobial, colistin
and an alternative antimicrobial compound, surfactin,
produced by a B. amyloliquefaciens ST34 strain, was
determined.
An environmental A. baumannii strain was, however,
not available to include in the analysis and was isolated
from a stream located in a local informal settlement
using growth media specific for Campylobacter species
[32]. It is hypothesised that the isolation of A. baumannii
could be attributed to the presence of antimicrobials in
both the Modified Preston Campylobacter (polymyxin B, ri-
fampicin, trimethoprim, and amphotericin B) and Modified
Karmali (cefoperazone, vancomycin and amphotericin B)
Selective Supplements. While the rifampicin, trimethoprim
and polymyxin B are effective in inhibiting the growth of
gram-negative bacteria, it should be noted that A. bauman-
nii is known to exhibit rifampicin resistance [36, 37], tri-
methoprim resistance [37, 38] and remains viable at a
polymyxin B concentration of 2mg/L according to the
CLSI [34] breakpoints. While this bacterium is classified as
a strict aerobe and is predominantly associated with clinical
settings [39], Fernando et al. [32] also recommended that,
for the isolation of A. baumannii from environmental sam-
ples, cultures should be incubated under microaerophilic
conditions. Culturing conditions employed by Fernando
et al. [32] were thus successfully employed in the current
study for the isolation of A. baumannii from environmental
samples, contributing to the evidence of the existence of
this pathogen in extra-hospital reservoirs. Antimicrobial
susceptibility analysis was subsequently conducted to ex-
plore the resistance profiles of clinical, environmental and
control strains of A. baumannii, P. aeruginosa, E. coli and
K. pneumoniae.
Multidrug-resistant (MDR) strains of A. baumannii
are resistant to three classes of antibiotics namely, β-
lactam antibiotics (all penicillins and cephalosporins),
fluoroquinolones and aminoglycosides, while extreme
drug resistant (XDR) strains are resistant to the previ-
ously mentioned three classes of antibiotics as well as to
carbapenems [40]. Results from the study then indicated
that while the reference isolate AB 1 and the environ-
mental isolate AB 6, displayed variable resistance, sus-
ceptibility and intermediate susceptibility profiles, the
four clinical A. baumannii isolates (AB 2 – AB 5) were
resistant > 90% of the antibiotics analysed (Additional
file 1: Table S2) and were subsequently classified as
XDR. A study by Chen et al. [41] similarly indicated that
clinical A. baumannii isolates exhibit resistance to
specifically β-lactams, fluoroquinolones, aminoglycosides
and carbapenems. While further research is required, it
is hypothesised that the XDR profile displayed by the
clinical A. baumannii isolates can be attributed to the
presence of multiple resistance mechanisms including β-
lactamases [e.g. OXA-51-like enzymes OXA-51-like
enzymes and a non-inducible chromosomal AmpC cepha-
losporinase (ADC1–7)] and aminoglycoside-modifying en-
zymes [e.g. acetyltransferase (AATs), nucleotidyltransferases
(ANTs) and phosphotransferases (APHs)], membrane
permeability alterations (e.g. loss of OMPs) or the overex-
pression or activation of multidrug efflux systems (e.g.
AdeABC and AdeIJK) [2]. Moreover, antibiotic resistance in
A. baumannii has been attributed to the alteration of the
penicillin-binding proteins, DNA gyrase and topoisomerase
IV mutations, tetracycline ribosomal protection protein and
the involvement of dihydrofolate reductase in trimethoprim
resistance [2, 4].
While based on the EUCAST [33] and CLSI [34] clas-
sification guidelines, the reference (EC 1), environmental
(EC 4 to EC 7) and one clinical E. coli isolate (EC 3)
were mostly susceptible to the antibiotics analysed (Fig. 1),
the clinical E. coli isolate EC 2 exhibited resistance to β-
lactams, fluoroquinolones and aminoglycosides and was
characterised as MDR. The results obtained in the current
study for EC 2 were also comparable to the study con-
ducted by Yassin et al. [42], where clinical E. coli isolates
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were characterised as aztreonam, ceftazidime, cefotaxime
and ciprofloxacin resistant. Moreover, while the clinical
isolate EC 3 was resistant to ciprofloxacin [33], aztreonam
and cefotaxime and both clinical isolates were resistant to
tetracycline [34], it is hypothesised that the multidrug
resistance displayed by the EC 2 isolate could also
possibly be attributed to the presence of β-lactamases,
aminoglycoside-modifying-enzymes and multidrug ef-
flux pumps [43–45]. The β-lactamases and extended
spectrum beta-lactamases (ESBLs) are primarily re-
sponsible for the hydrolysis of expanded spectrum
cephalosporins (e.g. cefotaxime, cefepime and ceftazi-
dime). Additionally, the AcrAB-TolC efflux pump,
present in specifically MDR E. coli strains, can effect-
ively remove fluoroquinolones and β-lactams from the
cell [46].
Based on the antimicrobial susceptibility analysis ob-
tained (Fig. 1), the reference KP 1 and clinical KP 2 and
KP 3 isolates were also classified as MDR as they exhib-
ited resistance to the three antibiotic classes β-lactams,
fluoroquinolones and aminoglycosides. However, the
clinical KP 4 isolate was classified as XDR as it exhibited
resistance to the three antibiotic classes including carba-
penems [imipenem (IMP)]. These results were compar-
able to a study conducted by Vasaikar et al. [46], where
they characterised clinical K. pneumoniae isolates exhi-
biting cephalosporin and aminoglycoside resistance,
amongst other antibiotics. Similar to A. baumannii, the
resistance profile displayed by the MDR and XDR K.
pneumoniae isolates may be attributed to the presence
of multiple resistance mechanisms including β-lactamases
[e.g. metallo-β-lactamases and expanded-spectrum oxacil-
linases (OXA-48)], aminoglycoside-modifying enzymes
(e.g. AATs, ANTs and APHs) and the overexpression or
activation of multidrug efflux systems (e.g. AcrAB multi-
drug efflux system) [2, 16, 47].
Results obtained also indicated that based on the
EUCAST [33] breakpoints, the P. aeruginosa clinical iso-
late PA 3 should be classified as XDR as it exhibited re-
sistance to β-lactams, fluoroquinolones, aminoglycosides
and carbapenems. Penicillins (piperacillin-tazobactam or
ticarcillin-clavulanate), cephalosporins (ceftazidime, cefe-
pime or cefoperazone), monobactams (aztreonam),
fluoroquinolones (ciprofloxacin or levofloxacin), carba-
penems (imipenem, doripenem or meropenem), amino-
glycosides (gentamicin, tobramycin or amikacin) and
polymyxins (polymyxin B or colistin) are commonly used
in the treatment of P. aeruginosa associated infections [47].
Pseudomonas aeruginosa is however, inherently resistant to
a multitude of antibiotic classes including carbapenems, β-
lactams, fluoroquinolones, aminoglycosides, and poly-
myxins [48, 49]. The primary antibiotic resistance mecha-
nisms in P. aeruginosa have been identified as; the presence
of β-lactamase enzymes (e.g. metallo-β-lactamases, AmpC,
PSE-1 and PSE-4), aminoglycoside-modifying enzymes (e.g.
AATs, ANTs and APHs), efflux systems (e.g. MexCD-OprJ,
MexXY-OprM and MexAB-OprM) and permeability alter-
ations (e.g. OprD porin deletion) [9, 50, 51].
The MIC of 16 representative MDR and XDR isolates
(Table 1), against the last resort antibiotic colistin, was
subsequently determined. These isolates were also
screened for the mobilised colistin resistance genes
(mcr-1 to mcr-4). While a colistin MIC of ≥4 mg/L was
recorded for 12 of the 16 isolates, only one strain (EC 3)
was found to harbour a colistin resistance gene. It was
also interesting to note that 75% of the A. baumannii
and 20% of the E. coli strains analysed were still suscep-
tible to colistin, while 100% of the K. pneumoniae and P.
aeruginosa strains were resistant. Research has, indicated
that resistance to colistin can be attributed to one of
three possible mechanisms [3, 52]. The first involves the
recently discovered colistin resistance mechanism associ-
ated with the mcr genes; the second mechanism involves
the modification of the lipid A moiety of the lipopolysac-
charide (LPS) mediated by mutation and/or over-
expression in the two-component system pmrA/pmrB in
response to environmental stimuli; while the third mech-
anism involves the complete loss of the LPS resulting
from either a mutation of insertional inactivation of the
lipid A biosynthesis genes lpxA, lpxC or lpxD. It is thus
hypothesised that one or more of these mechanisms
could have been expressed in the strains exhibiting colis-
tin resistance.
Overall, results in the current study indicated that in-
creased antibiotic and colistin resistance was observed
amongst the clinical isolates of the “WHO Priority 1:
Critical group” organisms, followed by the environmen-
tal and reference strains. Although antibiotic resistance
is complex and multifactorial in nature, the increased re-
sistance rates observed amongst the clinical isolates, in
comparison to the environmental and reference isolates,
could be attributed to the level of exposure of the patho-
genic population to antimicrobials [53, 54]. Subsequently,
the multitude of antimicrobials used in the clinical setting
could have served as selectors for resistance genes, which
are disseminated via horizontal gene transfer (HGT) or
more specifically transformation, transduction and conjuga-
tion [53–55]. Furthermore, the prevalence of nosocomial
infections caused by antibiotic resistant gram-negative bac-
teria has been associated with treatment failure, increased
length of stay, significantly higher total hospital cost and in-
creased mortality [56–58]. Cosgrove et al. [59] investigated
the increased cost associated with the development of re-
sistance during treatment. The authors found that patients
infected with Enterobacter species, which developed
expanded-spectrum cephalosporin resistance during anti-
microbial treatment, had an average hospital stay of 9 days
resulting in a higher hospital cost compared to the control
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group. Additionally, a study conducted by Kollef et al. [56]
investigated the relationship between nosocomial infections
that were not being effectively treated (termed inadequate
antimicrobial therapies) and the emergence of infections
caused by antibiotic resistant bacteria. Numerous corrective
practices such as limiting the use of broad-spectrum
antibiotics, applying antibiotic practice guidelines, rapid
microbiological diagnostic methods and consulting in-
fectious disease specialists, were outlined to curtail the
development of antibiotic resistance in clinically im-
portant pathogens [56].
However, while the implementation of these clinical
practices in restricting the incidence of nosocomial infec-
tions caused by antibiotic resistant bacteria is crucial, mea-
sures to combat MDR and XDR bacteria are still required.
As indicated, Ndlovu et al. [27] isolated the B. amylolique-
faciens ST34 strain from a WWTP in Stellenbosch. The
UPLC-MS spectra of the ST34 extract confirmed that the
biosurfactant produced displayed a profile similar to that
of the surfactin standard (Additional file 1: Figure S2).
The ESI-MS spectrum of the ST34 extract and the surfac-
tin standard revealed five groups of analogue molecules
(Additional file 1: Figure S2). As research has indicated
that lipopeptides such as surfactin, exhibit broad-
spectrum antimicrobial activity [28], the susceptibility of
the MDR and XDR WHO “Priority 1: Critical group” or-
ganisms, A. baumannii, P. aeruginosa, E. coli and K. pneu-
moniae strains to the crude surfactin extract produced by
ST34 was determined. Antibacterial activity was observed
against all the MDR and XDR strains in this study
(Table 1), with varying diameters for the zones of inhib-
ition recorded. Similar results were observed in a study
conducted by Ndlovu et al. [27], where 100% antimicrobial
activity of the surfactin extract obtained from B. amyloli-
quefaciens ST34, against a panel of gram-negative organ-
isms, including antibiotic-resistant strains, was observed.
A surfactin produced by the B. amyloliquefaciens M1
strain also exhibited broad-spectrum antibacterial activity
against pathogens of the Vibrio species with MDR profiles
[60]. Moreover, a surfactin produced by a B. subtilis strain
was successfully shown to kill larval and pupal stages of
the mosquito species Anopheles stephensi, Aedesaegypti
and Culexquinquefasciatus, highlighting the potential of
this biosurfactant as a prophylactic agent in the prevention
of malaria [61]. Furthermore, while Hoefler et al. [62] ob-
served resistance of test strains against surfactin (during
the co-culturing of B. subtilis and Streptomyces species
Mg1), which was ultimately attributed to the ability of
Streptomyces to synthesise a surfactin hydrolysing enzyme,
it is crucial to note that to date, limited resistance against
various lipopeptides has been observed [30, 63]. Thus,
while various clinical, environmental and control WHO
Critical Priority List Bacteria were classified as MDR and
XDR, based on their antibiograms, and colistin resistant,
these isolates were susceptible to the surfactin crude ex-
tract produced by the B. amyloliquefaciens ST34 strain.
Future studies will aim at purifying the surfactin homo-
logues, determining the antimicrobial activity of the puri-
fied surfactin and subsequently determining the MIC’s.
Conclusion
Clinical isolates of A. baumannii, P. aeruginosa, E. coli
and K. pneumoniae exhibited increased antibiotic resist-
ance profiles, compared to environmental and reference
strains. Moreover, XDR and MDR isolates of clinical ori-
gin exhibited higher colistin resistance compared to envir-
onmental and references isolates. It was hypothesised that
these resistant isolates were pre-exposed to the antibiotic
classes and colistin in the clinical environments and may
have acquired resistance through horizontal gene transfer.
Results also indicated that the WHO Critical Priority List
of Antibiotic-Resistant Bacteria are susceptible to surfactin
produced by the B. amyloliquefaciens ST34 strain. Based
on results obtained in the current study and previous
research, this lipopeptide may possibly be exploited as an
alternative antimicrobial against MDR or XDR gram-
negative bacteria classified as “Priority 1: Critical group”
organisms. To broaden the analysis of the antimicrobial
activity of surfactin, the susceptibility of the “Priority 2:
High” and “Priority 3: Medium” groups listed in the WHO
Report [1] should also be determined. Future research
should, however, focus on determining the cytotoxicity of
surfactin analogues to elucidate the use of this biosurfac-
tant as a chemotherapeutic agent and as a topical agent in
the treatment of cutaneous or subcutaneous infections
and for the coating or pre-treatment of medical equip-
ment and devices for the prevention of biofilm formation.
Methods
Bacterial isolates
The A. baumannii [AB 1; ATCC (American Type Cul-
ture Collection) 19,606], P. aeruginosa (PA 1; ATCC
27853), K. pneumoniae (KP 1: ATCC 10031) and E. coli
(EC 1; ATCC 13706) reference strains used in the
current study were available in the Khan Laboratory
Culture Collection (Additional file 1: Table S1). Clinical
isolates of the respective organisms were obtained from
either the Department of Biomedical Sciences at the
Cape Peninsula University of Technology (CPUT) or
the Department of Pathology (Division of Medical
Microbiology), Stellenbosch University. In addition, en-
vironmental isolates of K. pneumoniae, P. aeruginosa
and E. coli were obtained from the Khan Laboratory
Culture Collection (Additional file 1: Table S1). These
isolates were obtained from various environmental
sources such as surface water, rainwater and solar pas-
teurized rainwater.
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Environmental isolates of A. baumannii were however,
not available in the Khan Laboratory Culture Collection
and various environmental samples were collected for
the isolation of this organism. Wastewater samples (1 L)
were collected in sterile Schott bottles from the influent
of the Stellenbosch Wastewater Treatment Plant
(WWTP, GPS co-ordinates − 33.943505, 18.824584) in
Stellenbosch, Western Cape as described by Ndlovu
et al. [64]. Additionally, a 1 L water sample was collected
from the Plankenburg River (GPS co-ordinates −
33.927761, 18.850544) and a 1 L surface run-off water
sample was collected from a stream in Enkanini informal
settlement (GPS co-ordinates − 33.924120; 18.847618) in
Stellenbosch. Furthermore, sediment and soil samples
were collected from the river and surface run-off stream
by removing approximately 25 cm2 of topsoil and placing
the soil in sterile 50 mL falcon tubes. To select for and
isolate A. baumannii, an enrichment step was used as
outlined by Fernando et al. [32]. Following primary en-
richment, cultures (100 μL) were spread plated onto
Campylobacter Agar Base (CAB) containing a Modified
Karmali Selective Supplement [cefoperazone (32 mg/L),
vancomycin (20 mg/L) and amphotericin B (10 mg/L)]
(Oxoid, USA). The spread plates were incubated at 37 °C
for 24–48 h under microaerophilic conditions. After the
initial isolation, morphologically distinct colonies were
further purified by streaking onto CAB and Nutrient
Agar (NA; Biolab, Merck) to obtain pure cultures for
identification.
Genomic DNA extraction and conventional polymerase
chain reaction
Genomic DNA was extracted from the isolates obtained
from the environmental samples as well as all the refer-
ence, clinical and environmental Khan Laboratory Culture
Collection isolates (Additional file 1: Table S1) using the
boiling method as outlined by Ndlovu et al. [65].
Genomic DNA from all the reference, clinical and en-
vironmental isolates was used in genus or species-
specific conventional PCR assays, as a quality control
step, to identify all the isolates (Table 3). The PCR mix-
ture for the identification of A. baumannii, E. coli, K.
pneumoniae and P. aeruginosa isolates consisted of a
final volume of 25 μL and contained: 1X Green GoTaq®
Flexi buffer (Promega, Madison, Wi, USA); 0.75 U
GoTaq® G2 DNA polymerase (A. baumannii) (Promega)
or 1.5 U GoTaq® G2 DNA polymerase (E. coli, K. pneu-
moniae and P. aeruginosa) (Promega); 0.1 mM of the
deoxynucleoside triphosphate (dNTP) mix (A. bauman-
nii, K. pneumoniae and P. aeruginosa) (Thermo Scien-
tific, Hudson) or 0.2 mM dNTP mix (E. coli) (Thermo
Scientific); 2 mM MgCl2 (A. baumannii, K. pneumoniae
and P. aeruginosa) (Promega) or 1.5 mM MgCl2 (E. coli)
(Promega); 0.8 μM of the respective forward and reverse
primers (Table 3, A. baumannii and K. pneumoniae),
0.2 μM of the respective forward and reverse primers
(Table 3, E. coli) or 0.5 μM of the respective forward and
reverse primers (Table 3, P. aeruginosa); with the follow-
ing template DNA volumes – 2 μL (E. coli), 2.5 μL (A.
baumannii) and 5 μL (K. pneumoniae and P. aerugi-
nosa). Sterile distilled H2O was used as a negative con-
trol, while the genomic DNA extracted from the A.
baumannii ATCC 19606, E. coli ATCC 13706, K. pneu-
moniae ATCC 10031 and P. aeruginosa ATCC 27853
reference strains served as the positive controls. Amplifi-
cation was performed according to the amplification
conditions outlined in Table 3, using a T100™ Thermal
Cycler (Bio-Rad Laboratories, Hercules, CA, USA).
Following amplification, the PCR products were ana-
lysed by gel electrophoreses [80 Volts (V) for 60 min]
using 0.8% agarose (SeaKem® LE Agarose; Lonza) con-
taining 0.5 μg/mL ethidium bromide in a 1X Tris borate
ethylenediaminetetraacetic acid (TBE) buffer. Once the
DNA band size of the PCR products were confirmed,
representative PCR products were purified and concen-
trated using the Wizard® SV Gel and PCR Clean-up Sys-
tem (Promega) according to the manufacturer’s
instructions. The cleaned PCR products were sent to the
Central Analytical Facility (CAF) at Stellenbosch Univer-
sity for sequencing using the BigDye Terminator Version
3.1 Sequencing Kit (Applied Biosystems®, Foster City,
USA). The chromatograms of each sequence were exam-
ined using FinchTV version 1.4.0 software and sequence
identification was completed using the National Center
for Biotechnology Information (NCBI), Basic Local
Alignment Search Tool (BLAST), available at http://
blast.ncbi.nlm.nih.gov/Blast.cgi [70].
Table 3 Primer sequences and PCR cycling conditions
for the conventional PCR assays and for the identifica-
tion of the mobilised colistin resistance genes.
Kirby-Bauer antibiotic assays
To determine the antibiotic resistance profiles of all the
clinical, environmental and reference strains, the organ-
isms were re-streaked from either glycerol stocks (40%
glycerol stored at − 80 °C) or CAB plates onto NA and
were incubated at 37 °C for 18–24 h. Subsequently, all
the isolates were inoculated into 10 mL LB broth and
were grown overnight at 37 °C. Following the overnight
incubation, the optical density (OD) of the bacterial sus-
pensions were measured using a T60 Visible Spectro-
photometer (PG-Instruments Limited, Leicester, UK) at
625 nm. The OD625 of the suspensions was adjusted
using LB broth to 0.08–0.1, which corresponded to ap-
proximately 1.5 × 108 colony forming units (CFU)/mL
(EUCAST) [33]. One hundred microlitres of each ad-
justed suspension was subsequently spread plated onto
Mueller-Hinton agar (not cation-adjusted) (MHA,
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Biolab, Merck). Commercially-prepared, fixed concentra-
tion, antibiotic discs (Oxoid, USA) [e.g. amikacin (30 μg),
ampicillin (10 μg), aztreonam (30 μg), cefepime (30 μg),
cefotaxime (30 μg), ceftazidime (30 μg), ciprofloxacin
(5 μg), gentamicin (10 μg), imipenem (10 μg), levofloxa-
cin (5 μg), meropemen (10 μg), piperacillin-tazobactam
(103.9 / 11.3 μg) and tetracycline (30 μg)] were placed
onto the surface of the agar media [71].The respective
bacterial isolates were subjected to various antibiotics as
outlined in Additional file 1: Table S2, with zones of in-
hibition delineated by either the EUCAST [33] or CLSI
[34] guidelines. All the antibiotic disc assays were per-
formed in triplicate and the plates were incubated at
37 °C for 18–24 h. Following incubation, the diameter of
the zone of inhibition around each antibiotic disc was
measured to the closest millimetre. These measurements
were compared to the clinical breakpoints as outlined in
the EUCAST [33] and CLSI [34] standards to determine
if the organisms were resistant, intermediately suscep-
tible or susceptible to the tested antibiotics. Based on
the resistance profiles, isolates were classified as multi-
drug resistant (MDR) or extensively resistant (XDR).
Multidrug resistance (MDR) referred to resistance to
three classes of antibiotics namely β-lactam antibiotics
(all penicillins and cephalosporins), fluoroquinolones
and aminoglycosides, whereas XDR referred to the re-
sistance to the previously mentioned three classes of an-
tibiotics as well as to carbapenems [40].
Colistin minimum inhibitory concentration
Based on the results obtained for the antibiotic disc as-
says, isolates displaying antibiotic resistance were further
screened for colistin resistance using the methodology
described by the EUCAST [33] and CLSI [34]. Serial di-
lutions of the colistin sulphate stock solution (10.00 mg/
mL) (VWR Life Sciences, Philadelphia, USA) were pre-
pared in milliQ water corresponding to a concentration
range of 0.06 mg/L to 4 mg/L for A. baumannii, E. coli
and K. pneumoniae and 0.06 mg/L to 8 mg/L for P. aeru-
ginosa [33]. Cell suspensions of the isolates were pre-
pared and diluted in LB broth to obtain an OD625 of
0.08–0.1 [33]. One hundred microlitres of cation-
adjusted Mueller–Hinton Broth 2 (CAMHB; Biolab,
Merck) and 100 μL of each of the colistin dilutions were
pipetted into the wells of a Nunclon™ Delta Surface 96-
well tissue culture microtitre plate (Nunc™, Roskilde,
Denmark). Following the addition of the CAMHB and
colistin, 10 μL of the adjusted OD bacterial inoculums
was added to the respective wells. In addition, a positive
control (organism in CAMHB without colistin) and a
sterility control (CAMHB) were included for each mini-
mum inhibitory concentration (MIC) assay. Escherichia
coli EC3 (colistin resistant) and P. aeruginosa ATCC
27853 (colistin sensitive) were included in all assays as
quality controls. The 96-well plates were incubated at
35 ± 2 °C for 20–24 h. The susceptibility of the organ-
isms to colistin was determined by measuring the optical
density of the samples at a wavelength of 600 nm
(OD600) before (t = 0) and after incubation (t = 24) using
a PowerWave™ Microplate Spectrophotometer (BioTek
Instruments, Vermont, USA). The percentage inhibition
was calculated as outlined in Poimenidou et al. [72]. The
MIC was determined as the minimum concentration of
the antimicrobial solution at which no increase of OD
(OD600 ~ 0 at t = 24) was observed. Subsequently, the
MIC was compared to the EUCAST [33] and CLSI [34]
breakpoints to determine the organism’s susceptibility or
resistance to colistin.
Multiplex PCR for Colistin resistance genes
All the bacterial isolates employed in the current study
(Additional file 1: Table S1) were screened for the
plasmid-mediated mobilised colistin resistance (mcr-1 to
mcr-4) genes as described by Rebelo et al. [19]. To con-
firm the presence of the mcr-1, mcr-2, mcr-3 or mcr-4
plasmid-mediated resistance genes, plasmid isolation
was performed for each of the colistin resistant organ-
isms using the PureYield™ Plasmid Miniprep System
(Promega, South Africa), according to the manufac-
turer’s instructions. For the amplification of the mcr-1 to
mcr-4 genes, each multiplex PCR mixture consisted of a
final volume of 25 μL, containing 1X Green GoTaq®
Flexi buffer, 2 mM MgCl2 (Promega), 0.1 mM of a dNTP
mix (Thermo Scientific), 0.2 μM of the respective for-
ward and reverse PCR primers (Table 3), 0.75 U GoTaq®
Flexi DNA polymerase (Promega) and 2 μL plasmid
DNA, per respective isolate. Amplification was per-
formed using a T100™ Thermal Cycler (Bio-Rad Labora-
tories, USA) using the PCR amplification conditions
outlined in Table 3. Plasmid DNA extracted from the E.
coli Tygerberg Hospital isolate (EC 3; mcr-1 positive)
and the P. aeruginosa ATCC 27853 isolate (PA 1; mcr-1
negative control) served as the positive and negative
controls for the mcr-1 gene. Sterile distilled H2O served
as the PCR negative control. The obtained PCR products
were visualised, purified, concentrated and sent to CAF
for sequencing as previously described.
Extraction, purification and characterisation of Surfactin
produced by the B. amyloliquefaciens ST34 strain
The B. amyloliquefaciens ST34 strain (collection number
SARCC 696 at the South African Rhizobium Culture
Collection), isolated by Ndlovu et al. [64] from the Stel-
lenbosch WWTP in the Western Cape, South Africa,
was used to obtain the antimicrobial lipopeptide surfac-
tin. The methods previously described by Ndlovu et al.
[27, 64] were used for the production, extraction and
characterisation of the crude extract obtained from B.
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amyloliquefaciens ST34. Briefly, B. amyloliquefaciens
ST34 was streaked onto NA plates which were incubated
at 37 °C for 18–24 h. Seed cultures were prepared in 5
mL sterile mineral salt medium (MSM; 0.1 KH2PO4,
0.1% K2HPO4, 0.02% MgSO4·7H2O, 0.002% CaCl2·2H2O,
0.005% FeCl3·6H2O and 0.2% NaNO3 and 3% glycerol,
with the pH adjusted to 6.8) with a single colony from
the NA cultures [27, 64]. The seed cultures were culti-
vated at 30 °C and 200 rpm for 18–24 h.
Following the preparation of the seed cultures, a 500mL
baffled flask containing 100mL MSM was inoculated with
a 2% cell suspension (OD600 = 0.7). Broth cultures were
incubated on an orbital shaker (New Brunswick, NY,
USA) at 120 rpm for 120 h at 30 °C. After 5 days, the cul-
tures (100mL) were centrifuged at 11305×g for 30min at
4 °C to remove microbial cells. The supernatant was re-
moved and subsequently acidified using hydrochloric acid
(Merck, Darmstadt, Germany) to a pH of 7.5, whereafter
it was stored at 4 °C to induce the precipitation of the bio-
surfactant. Using centrifugation at 11305×g for 30min at
4 °C the precipitate was harvested and washed with 50mL
milliQ water, thereafter the sample pH was adjusted to
7.5. Insoluble fractions were lyophilised using a freeze
dryer (Virtis Bechtop K, SP-Industries, NY, USA) and
were further extracted using 70% acetonitrile (Romil,
Waterbeach, England). This process was repeated thrice.
Following lyophilisation, crude extracts were stored at −
20 °C until characterisation.
Mass spectrometry analysis was performed at the CAF
of Stellenbosch University using a Waters Quadrupole
Time of Flight Synapt G2 (Waters Corporation, Milford,
USA) mass spectrometer. For UPLC-MS analysis, 3 μL of
the commercial surfactin standard (Sigma-Aldrich) and
the ST34 crude extract was injected and separated on a
UPLC C18 reverse-phase analytical column (Acquity
UPLC® HSS T3, 1.8 μm particle size, 2.1 × 150mm, Waters
corporation, Dublin, Ireland) at a flow rate of 0.300mL/
minute using 0.1% formic acid (A) to acetonitrile (B) gra-
dient [60% (A) from 0 to 0.5min for loading; a 40 to 95%
gradient (B) from 0.5 to 11min and then 95 to 40% (B)
from 15 to 18min] [65]. A capillary voltage of 3 kV, cone
voltage of 15 V and a temperature of 120 °C was utilised
during the UPLC-MS analysis of the analytes [27]. The
data acquisition was conducted in positive mode for the
MS-scanning of a second analyser through the m/z range
of 200–3000 Da. Data were analysed using Masslynx soft-
ware version 4.1 (Water Corporation, Milford, USA) and
the UPLC-MS profiles obtained for the crude extract was
compared to the surfactin (Sigma-Aldrich).
Antimicrobial activity of Surfactin: agar disc susceptibility
test
The susceptibility of the reference, clinical and environ-
mental bacterial strains to the crude extract (10.00mg/mL)
obtained from the B. amyloliquefaciens ST34 strain was de-
termined using the method outlined by Ndlovu et al. [27].
Briefly, the lyophilised ST34 crude extract was dis-
solved in 15% (v/v) methanol to obtain a concentra-
tion of 10.00 mg/mL. Antimicrobial discs (6 mm;
Oxoid, USA) were placed on the MHA after the test
isolates were spread plated onto the media and were
impregnated with 50 μL of the surfactin crude extract
(with approximately 9.98 μg surfactin in the crude ex-
tract). For each assay, a surfactin negative and posi-
tive control was included in the experiment for each
of the test organisms. The negative control consisted
of the test microorganism spread plated onto MHA
(Merck) with 15% (v/v) methanol impregnated filter
paper discs, while the positive control consisted of
the reference test organisms [AB 1, EC 1, KP 1 and
PA 1] spread plated onto MHA with commercial sur-
factin (1.00 mg/mL) (Sigma, USA) impregnated filter
paper discs added on top of the media. All the agar
plates were incubated for 24–48 h at 37 °C, whereafter
the diameters of the zones of inhibition around the
inoculated paper discs were measured and recorded.
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1186/s12866-019-1687-0.
Additional file 1: Table S1. Bacterial isolates utilised as test organisms
in this study. Table S2. Antibiotics used in the disc diffusion assay against
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based on the availability of EUCAST [33] or CLSI [34] breakpoint data.
Figure S1. Antibiotic susceptibility assays of four representative isolates,
A) A. baumannii AB1 (MEM1, CTX2, IMP3 and CIP4), B) E. coli EC1 (CTX1,
FEP2, LEV3 and IMP4), C) K. pneumoniae KP1 (LEV1, FEP2, CN3 and AK4) and D) P.
aeruginosa PA1 (IMP1, AK2, LEV3 and MEM4). The antibiotic susceptibility assay
of four represented isolates (A. baumannii, E. coli, K. pneumoniae and P.
aeruginosa) exposed to various antibiotics indicated in brackets. Figure S2.
The positive mean spectrum of the ESI-MS analysis generated with MaxEnt3
of the surfactin standard (A) and ST34 MSM extract (B) is shown. Masses are
indicated as [Mr + H] = m/z of singly charged species. Refer to Table 2 for
identities of Srf1 – Srf5 and the expected m/z and Mr values. The positive
mean spectrum of the ESI-MS analysis generated with MaxEnt3 of the surfactin
standard (A) and ST34 MSM extract (B) is shown. Masses are indicated as [Mr +
H] =m/z of singly charged species.
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